Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
- DOI
- 10.1111/dom.14234
- Published
- 2021 Feb
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.14234,
title = {Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.},
author = {Inzucchi SE and Davies MJ and Khunti K and Trivedi P and George JT and Zwiener I and Johansen OE and Sattar N},
year = {2021},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.14234},
url = {https://doi.org/10.1111/dom.14234}
}RIS
TY - JOUR TI - Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. AU - Inzucchi SE AU - Davies MJ AU - Khunti K AU - Trivedi P AU - George JT AU - Zwiener I AU - Johansen OE AU - Sattar N PY - 2021 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.14234 UR - https://doi.org/10.1111/dom.14234 ER -
APA
SE, I., MJ, D., K, K., P, T., JT, G., I, Z., OE, J., & N, S. (2021). Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.14234
Source records
- pubmed · retrieved 2026-09-27T09:25:41.011Z